{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:40:57Z","timestamp":1764103257743,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004826","name":"natural science foundation of beijing municipality","doi-asserted-by":"publisher","award":["7192071"],"award-info":[{"award-number":["7192071"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-021-00786-w","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T16:03:00Z","timestamp":1641484980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model"],"prefix":"10.1007","author":[{"given":"Xiangjun","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhe","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingchen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boran","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7282-1997","authenticated-orcid":false,"given":"Xinru","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"786_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ajh.22237","volume":"87","author":"SV Rajkumar","year":"2012","unstructured":"Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:78\u201388.","journal-title":"Am J Hematol"},{"key":"786_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ejh.12239","volume":"92","author":"A Alegre","year":"2014","unstructured":"Alegre A, Gironella M, Bail\u00e9n A, Giraldo P. Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. Eur J Haematol. 2014;92:181\u20138.","journal-title":"Eur J Haematol"},{"key":"786_CR3","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/17474086.2018.1531702","volume":"11","author":"N Kanellias","year":"2018","unstructured":"Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018;11:881\u20138.","journal-title":"Expert Rev Hematol"},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00223-017-0351-7","volume":"102","author":"ES Ring","year":"2018","unstructured":"Ring ES, Lawson MA, Snowden JA, Jolley I, Chantry AD. New agents in the treatment of myeloma bone disease. Calcif Tissue Int. 2018;102:196\u2013209.","journal-title":"Calcif Tissue Int"},{"key":"786_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/pharmaceutics10040202","volume":"10","author":"S Vallet","year":"2018","unstructured":"Vallet S, Filzmoser JM, Pecherstorfer M, Podar K. Myeloma bone disease: update on pathogenesis and novel treatment strategies. Pharmaceutics. 2018;10:202.","journal-title":"Pharmaceutics"},{"key":"786_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00586-006-0188-7","volume":"16","author":"SP Kelley","year":"2007","unstructured":"Kelley SP, Ashford RU, Rao AS, Dickson RA. Primary bone tumours of the spine: a 42-year survey from the leeds regional bone tumour registry. Eur Spine. 2007;16:405\u20139.","journal-title":"Eur Spine"},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/leu.2008.127","volume":"22","author":"MA Hussein","year":"2008","unstructured":"Hussein MA, Vrionis FD, Allison R, et al. The role of vertebral augmentation in multiple myeloma: international myeloma working group consensus statement. Leukemia. 2008;22:1479\u201314.","journal-title":"Leukemia"},{"key":"786_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/os.12267","volume":"8","author":"Surgeon's Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation","year":"2016","unstructured":"Surgeon\u2019s Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation. Consensus on surgical management of myeloma bone disease. Orthopaedic Surg. 2016;8:263\u20139.","journal-title":"Orthopaedic Surg"},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3171\/2014.9.SPINE14554","volume":"22","author":"PL Zadnik","year":"2015","unstructured":"Zadnik PL, Goodwin CR, Karami KJ, et al. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. J Neurosurg Spine. 2015;22:301\u20139.","journal-title":"J Neurosurg Spine"},{"issue":"Suppl 4","key":"786_CR10","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.injury.2016.07.047","volume":"47","author":"V Denaro","year":"2016","unstructured":"Denaro V, Denaro L, Albo E, Papapietro N, Piccioli A, Martino Di. Surgical management of spinal fractures and neurological involvement in patients with myeloma. Injury. 2016;47(Suppl 4):S49-s53.","journal-title":"Injury"},{"key":"786_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1302\/0301-620X.96B4.32629","volume":"96-b","author":"K Igarashi","year":"2014","unstructured":"Igarashi K, Yamamoto N, Shirai T, et al. The long-term outcome following the use of frozen autograft treated with liquid nitrogen in the management of bone and soft-tissue sarcomas. Bone Joint J. 2014;96-b:555\u201361.","journal-title":"Bone Joint J."},{"key":"786_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00113-015-0059-y","volume":"118","author":"KD K\u00fchn","year":"2015","unstructured":"K\u00fchn KD, H\u00f6ntzsch D. Augmentation with PMMA cement. Unfallchirurg. 2015;118:737\u201348.","journal-title":"Unfallchirurg"},{"key":"786_CR13","first-page":"10017","volume":"15","author":"J Shen","year":"2018","unstructured":"Shen J, Du X, Zhao L, Luo H, Xu Z. Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone\/soft tissue. Oncol Lett. 2018;15:10017\u201325.","journal-title":"Oncol Lett"},{"issue":"1","key":"786_CR14","first-page":"1276","volume":"12","author":"X Yao","year":"2019","unstructured":"Yao X, Wei Y, Luo H, Du X. Anti-myeloma properties and mechanism of polymethyl methacrylate bone cement and allograft bone in vitro. Int J Clin Exp Med. 2019;12(1):1276\u201381.","journal-title":"Int J Clin Exp Med"},{"key":"786_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/17474086.2020.1711730","volume":"13","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Bednarczyk M, Janikowska G. Heat shock proteins as a new, promising target of multiple myeloma therapy. Expert Rev Hematol. 2020;13:117\u201326.","journal-title":"Expert Rev Hematol"},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S1470-2045(13)70169-4","volume":"14","author":"R Garcia-Carbonero","year":"2013","unstructured":"Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358-369.","journal-title":"Lancet Oncol"},{"key":"786_CR17","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3892\/ol.2017.6355","volume":"14","author":"K Koto","year":"2017","unstructured":"Koto K, Murata H, Sawai Y, Ashihara E, Horii M, Kubo T. Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors. Oncol Lett. 2017;14:1648\u201356.","journal-title":"Oncol Lett"},{"key":"786_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/10245332.2018.1449338","volume":"23","author":"J Wang","year":"2018","unstructured":"Wang J, Li Y, Sun W, Liu J, Chen W. Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells. Hematology. 2018;23:620\u20135.","journal-title":"Hematology"},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"e135544","DOI":"10.1172\/jci.insight.135544","volume":"5","author":"L Huang","year":"2020","unstructured":"Huang L, Okada K, Takahashi S, Suzuki N, Shimada Y, Itoi E. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI insight. 2020;5:e135544.","journal-title":"JCI insight."},{"key":"786_CR20","first-page":"55","volume":"20","author":"T Tani","year":"2006","unstructured":"Tani T, Hatanaka K, Watanabe H, Asano Y, Yamagata H, Maruyama T. Doxorubicin-loaded calcium phosphate cement in the management of bone and soft tissue tumors. Vivo. 2006;20:55\u201360.","journal-title":"Vivo"},{"key":"786_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/10520290009047983","volume":"75","author":"S Matsui","year":"2000","unstructured":"Matsui S, Doseff A, Chau BN, et al. A modification of Mayer\u2019s tannic acid-ferric chloride staining method for demonstrating cellular membranous systems for light microscopy. Biotechnic Histochem. 2000;75:33\u201340.","journal-title":"Biotechnic Histochem"},{"key":"786_CR22","doi-asserted-by":"publisher","first-page":"21155","DOI":"10.1074\/jbc.274.30.21155","volume":"274","author":"DG Kirsch","year":"1999","unstructured":"Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biolog Chem. 1999;274:21155\u2013211.","journal-title":"J Biolog Chem"},{"key":"786_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2006.02.017","volume":"42","author":"C Jakob","year":"2006","unstructured":"Jakob C, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581\u201390.","journal-title":"Eur J Cancer"},{"key":"786_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000094829","volume":"13","author":"S Tsukahara","year":"2006","unstructured":"Tsukahara S, et al. Inhalation of low-level formaldehyde increases the Bcl-2\/Bax expression ratio in the hippocampus of immunologically sensitized mice. NeuroImmunoModulation. 2006;13:63\u20138.","journal-title":"NeuroImmunoModulation"},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/07357900802438585","volume":"27","author":"CA Odonkor","year":"2009","unstructured":"Odonkor CA, Achilefu S. Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy. Cancer Invest. 2009;27:417\u201329. https:\/\/doi.org\/10.1080\/07357900802438585.","journal-title":"Cancer Invest"},{"key":"786_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.07.021","volume":"406","author":"R Calero","year":"2017","unstructured":"Calero R, Morchon E, Martinez-Argudo I, Serrano R. Synergistic anti-tumor effect of 17AAG with the PI3K\/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett. 2017;406:1\u201311.","journal-title":"Cancer Lett"},{"key":"786_CR27","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00432-012-1247-6","volume":"138","author":"E Tavernier","year":"2012","unstructured":"Tavernier E, et al. HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents. J Cancer Res Clin Oncol. 2012;138:1753\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"786_CR28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/1568009619666190206120615","volume":"19","author":"X Zhang","year":"2019","unstructured":"Zhang X, Gao F, Zhong S. Combinatorial Inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant Pheochromocytoma. Curr Cancer Drug Targets. 2019;19:698\u2013706.","journal-title":"Curr Cancer Drug Targets"},{"key":"786_CR29","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","volume":"18","author":"K Yata","year":"2004","unstructured":"Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004;18:1891\u20137.","journal-title":"Leukemia"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-021-00786-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T16:06:08Z","timestamp":1641485168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-021-00786-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":29,"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1007\/s10238-021-00786-w","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"type":"print","value":"1591-8890"},{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"6 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Beijing Chao-Yang Hospital (Approval 2018-ke-259) and with the 1964 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}